Bone Boost SAN (160 cap)
Bone Boost is a carefully formulated combination of ingredients designed to strengthen and improve the function of bone, cartilage, and tendon. Below we’ll take a look at each of the components of Bone Boost and see how they function to improve the health of connective tissue. Its first ingredient is called:
Cissus quadrangularis is an ancient medicinal plant native to the hotter parts of Ceylon and India. It was prescribed in the ancient Ayurvedic texts as a general tonic and analgesic (painkiller), with specific bone fracture healing properties. Modern research has shed light on Cissus’ ability to speed bone healing by showing it acts as a glucocorticoid antagonist (1,2). Since anabolic/androgenic compounds are well known to act as antagonists to the glucocorticoid receptor as well as promote bone growth and fracture healing, it has been postulated that Cissus possesses anabolic and/or androgenic properties (1,3). In addition to speeding the remodeling process of the healing bone, Cissus also leads to a much faster increase in bone tensile strength. In clinical trials Cissus has led to a fracture healing time on the order of 55 to 33 percent of that of controls. That cissus exerts antiglucocorticoid properties is suggested by a number of studies where bones were weakened by treatment with cortisol, and upon administration of Cissus extract the cortisol induced weakening was halted, and the healing process begun.
With studies showing that hormone replacement therapy in postmenopausal women may increase the risk of breast cancer and heart disease, many women are looking at alternatives to estrogen to help prevent osteoporosis. Although there appears to be no published research showing that Cissus increases bone density in osteoporosis, or helps prevent the disease, the fact that the herb speeds recovery of fractures suggests that may increase bone density in osteoporosis as well. It would almost certainly help speed the recovery of fractures that are a common occurrence with osteoporosis. Chronic glucocorticoid therapy is a high risk factor for the development of osteoporosis. Glucocorticoids are believed to interfere with the action of osteoblasts, the cells that are responsible of the deposition of new bone material. The drug mefipristone (RU-486), an antiglucocorticoid as well as progesterone antagonist, has been successfully used to treat osteoporosis but the side effects, such as endometrial hyperplasia, are serious enough to preclude its routine use for the treatment of osteoporosis. Cissus seems to be devoid of such side effects and may prove to be a viable compound in osteoporosis treatment.
While the increased rate of bone healing may be of great significance to persons suffering from chronic diseases like osteoporosis (4), the antiglucocorticoid properties of Cissus are likely of much more interest to the average bodybuilder or athlete, since endogenous glucocorticoids, particularly cortisol, are not only catabolic to bone, but catabolize muscle tissue as well. Numerous studies over the years have suggested that glucocorticoids, including the body’s endogenous hormone cortisol, activate pathways that degrade not only bone, but skeletal muscle tissue as well. A recently published report documented exactly how glucocorticoids (including cortisol) induce muscle breakdown: They activate the so-called ubiquitin-proteasome pathway of proteolysis (5). This pathway of tissue breakdown is important for removing damaged and non-functional proteins. However, when it is overactive during periods of elevated cortisol (e.g disease states, stress, and overtraining) excess amounts of normal tissue are broken down as well. By exerting an anabolic, antiglucocorticoid effect Cissus helps preserve muscle tissue during times of physical and emotional stress.
Although the bulk of the research on Cissus centers on bone healing, the possibility exists that Cissus may improve the healing rate of connective tissue in general, including tendons and cartilage. If this were the case it would be of even greater benefit to bodybuilders and athletes. Numerous anecdotal reports by Cissus users claim rapid healing of long standing tendenitis.
Besides the above-mentioned properties of Cissus, the plant is also rich in the vitamins/antioxidants vitamin C and beta-carotene. As analyzed, Cissus quadrangularis contained ascorbic acid 479 mg, and carotene 267 units per 100g of freshly prepared paste in addition to calcium oxalate (6).
The typical recommended daily dosage of Cissus extract is between 500 and 1000 mg, depending on the concentration of the extract and the severity of symptoms. For the powder of the dried plant, the Ayurvedic texts recommend a dosage of 3 to 6 grams to accelerate fracture healing. Safety studies in rats showed no toxic effects at dosages as high as 2000 mg/kg of body weight. So not only is Cissus efficacious, it is also quite safe, in either the dried powder form or the commercially available extract.
Cissus also possess analgesic properties on an mg per mg basis comparable to aspirin or anti-inflammatory drugs like ibuprofen. Cissus quadrangularis constitutes one of the ingredients of an Ayurvedic preparation, `Laksha Gogglu', which has been proved to be highly effective in relieving pain, reduction of swelling and promoting the process of healing of the simple fractures as well as in curing the allied disorders associated with fractures (7). The mechanism through which Cissus exerts its analgesic and anti-inflammatory properties has not been well characterized. It may act centrally, or by preventing the conversion of arachidonic acid to inflammatory prostaglandins.
MSM, or methylsulfonylmethane is a chemical cousin (a metabolite, actually) of the familiar anti-inflammatory compound DMSO (dimethyl sulfoxide) and shares DMSO’s ability to suppress the inflammatory response, yet lacks the unpleasant garlic like odor of typical DMSO.
MSM has been used experimentally to treat a number of disorders associated with an overactive immune response, including allergies and arthritis. It is the latter that is of particular interest to us. In one study of patients suffering from arthritis, compared to placebo subjects given MSM showed noticeable improvement in symptoms (8). An unpublished study by Lawrence et al assessed the use of MSM in degenerative arthritis. At a dose of 750 mg per day the study group showed an 80 percent improvement after six weeks compared to a 20 percent improvement in the placebo group (9).
MSM has been shown in vitro to act as a cancer-preventing agent. It appears to possess the ability to limit cellular proliferation (10).
Glucosamine is a so-called aminomonosaccharide, consisting of a combination of glutamine and glucose. Glucosamine taken orally is concentrated in joint cartilage where the body uses it as a substrate for cartilage glucosaminoglycan synthesis. Reviews of the clinical trials and metaanalyses support the efficacy of glucosamine to support joint health (11,12).
Besides serving as a building block for articular cartilage, glucosamine has been shown to suppress the formation of the inflammatory compounds PGE(2) and nitric oxide (15) produced by immune cells (This is not to be confused with the nitric oxide produced by working muscles and NO supplements. The latter two act as vasodilators and are beneficial for blood and nutrient delivery to exercising muscle.) Chondroitin sulfate, (CS) discussed below, shares this property, which may provide a plausible explanation for their purported anti-inflammatory actions. In fact, research in animals indicates that the combination of glucosamine and CS may be more effective in preventing or treating osteoarthritis than either product alone (16).
Chondroitin Sulfate (CS) is a polysaccharide consisting of linear repeating units of galactosamine and glucoronic acid. CS is found in human bone, cartilage, skin, cornea and arterial walls. Whereas glucosamine is primarily thought to promote the repair and formation of cartilage, CS is believed to promote water retention and elasticity in cartilage and inhibit enzymes that break down cartilage (8). However, as mentioned above, recent research indicates CS may share glucosamine’s anti-inflammatory properties.
Microcrystalline Hydroxyapatite Concentrate (MCHC) is a highly bioavailable source of calcium and phosphorus, the mineral building blocks of bone. Several studies involving corticosteroid induced bone loss have shown that MCHC can significantly reduce the rate of bone loss (17, 18). MCHC is the actual matrix that makes up much of the bones’ structure and provides over 45 whole bone proteins. Supplementing with MCHC provides calcium, phosphorus, and trace amounts of other minerals. As with Cissus, research has shown MCHC to be effective at limiting the bone loss associated with high levels of cortisol. For this reason it may be of particular interest to those subject to stress associated with physical training, or simply the stress of everyday life. Although alternate forms of calcium are available for supplementation, such as calcium carbonate, MCHC based calcium supplementation has been shown to have better effects on bone density than other forms of calcium (19,20).
Vitamin D is well known as a hormone involved in mineral metabolism and bone growth. Its best-known effect is to facilitate intestinal absorption of calcium, although it also stimulates absorption of phosphate and magnesium ions (21, 22). In the absence of vitamin D, dietary calcium is not absorbed efficiently. Vitamin D stimulates the _expression of a number of proteins involved in transporting calcium from the interior (lumen) of the intestine, across the epithelial cells and into blood. The best studied of these calcium transporters is calbindin, an intracellular protein that shuttles calcium across the intestinal epithelial cell.
Numerous effects of vitamin D on bone have been demonstrated. As a transcriptional regulator of bone matrix proteins, it induces the _expression of osteocalcin and suppresses synthesis of type I collagen. In cell cultures, vitamin D stimulates differentiation of osteoclasts, cells involved in bone metabolism. However, studies of humans and animals with vitamin D deficiency or mutations in the vitamin D receptor suggest that these effects are perhaps not of major physiologic importance, and that the crucial effect of vitamin D on bone is to provide the proper balance of calcium and phosphorus to support mineralization. As a component of Bone Boost, Vitamin D improves the already high bioavailability of MCHC.
Experts have shown concern that dietary levels of Vitamin D are insufficient to stave off osteoporosis in men and have recommended a minimum of 400 – 800 IU daily during adulthood to prevent the development of osteoporosis (23).
Besides aiding mineral transport and possibly modulating the activity of bone and collagen producing cells, an interesting new function of Vitamin D is being investigated. We are all quite familiar with the importance of estrogen to bone strength. Research has shown that vitamin D may increase aromatase activity within bone itself, enhancing the local conversion of androgens to estrogens in both men and women. This process does not increase plasma levels of estrogen, but rather limits its production and concentration to bone. (24).
Additionally, research, presented at the 2005 Multidisciplinary Prostate Cancer Symposium in the US, is the first to demonstrate a link between vitamin D and prevention of prostate cancer. Men with higher levels of vitamin D in their blood were almost half as likely to develop aggressive forms of prostate cancer as those with lower amounts, reported researchers at the conference held the week of February 21, 2005.
"Our findings suggest that vitamin D plays an important protective role against prostate cancer, especially clinically aggressive disease," said lead investigator Dr Haojie Li, a research fellow at Brigham and Women's Hospital and Harvard University School of Public Health.
Besides possibly preventing prostate cancer, the biologically active form of vitamin D found in Bone Boost, Vitamin D3, has shown promise as well in in vitro studies of benign prostatic hyperplasia, the much more common disease that afflicts older men and in particular users of anabolic steroids (since androgens stimulate prostate growth). In studies, Vitamin D3 slowed the growth of benign prostate cells significantly.
To quote from one such report,
"The activated form of vitamin D, vitamin D3, seems to be a promising candidate for BPH therapy. Indeed, it has emerged as one of the most potent growth regulatory molecules in prostate. Vitamin D3 binds to nuclear vitamin D receptor, present in both epithelial and stromal cells, and inhibits growth" (25).
Chopra SS, Patel MR, Awadhiya RP. Studies of Cissus quadrangularis in experimental fracture repair : a histopathological study Indian J Med Res. 1976 Sep;64(9):1365-8
Chopra SS, Patel MR, Gupta LP, Datta IC. Studies on Cissus quadrangularis in experimental fracture repair: effect on chemical parameters in blood Indian J Med Res. 1975 Jun;63(6):824-8.
PRASAD GC, UDUPA KN. EFFECT OF CISSUS QUADRANGULARIS ON THE HEALING OF CORTISONE TREATED FRACTURES. Indian J Med Res. 1963 Jul;51:667-76.
Shirwaikar A, Khan S, Malini S. Antiosteoporotic effect of ethanol extract of Cissus quadrangularis Linn. on ovariectomized rat. J Ethnopharmacol. 2003 Dec;89(2-3):245-50.
Combaret L, Taillandier D, Dardevet D, Bechet D, Ralliere C, Claustre A, Grizard J, Attaix D Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles. Biochem J. 2004 Feb 15;378(Pt 1):239-46.
Chidambara Murthy KN, Vanitha A, Mahadeva Swamy M, Ravishankar GA. Antioxidant and antimicrobial activity of Cissus quadrangularis L. J Med Food. 2003 Summer;6(2):99-105.
Panda, J Res Ayurv Siddha, 1990, 11, 7
Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev. 2002 Feb;7(1):22-44
Methylsulfonylmethane (MSM). Monograph. Altern Med Rev. 2003 Nov;8(4):438-41.
Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res. 2003 Jan-Feb;23(1A):453-8.
McAlindon TE, LaValley MP, Felson DT. Efficacy of glucosamine and chondroitin for treatment of osteoarthritis JAMA. 2000 Sep 13;284(10):1241.
Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother. 2005 Jun;39(6):1080-7.
Biggee BA, McAlindon T. Glucosamine for osteoarthritis: part I, review of the clinical evidence. Med Health R I. 2004 Jun;87(6):176-9.
McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am. 2003 Nov;29(4):789-801.
Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene _expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage. 2005 May;13(5):387-94
Dechant JE, Baxter GM, Frisbie DD, Trotter GW, McIlwraith CW. Effects of glucosamine hydrochloride and chondroitin sulphate, alone and in combination, on normal and interleukin-1 conditioned equine articular cartilage explant metabolism. Equine Vet J. 2005 May;37(3):227-31.
Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline hydroxyapatite compound ('Ossopan') in the prevention of osteoporosis due to corticosteroid therapy. Curr Med Res Opin. 1984;8(10):734-42.
Stellon A, Davies A, Webb A, Williams R. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med J. 1985 Sep;61(719):791-6.
Rьegsegger P, Keller A, Dambacher MA Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporos Int 1995;5:30–4.
Albertazzi P, Steel SA, Howarth EM, Purdie DW. Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial. Climacteric. 2004 Mar;7(1):33-40.
DeLuca HF and Zierold C. Mechanisms and functions of vitamin D. Nutr Rev 1998;56:S4-10.
Reichel H, Koeffler H, Norman AW. The role of vitamin D endocrine system in health and disease. N Engl J Med 1989;320:980-91.
Olszynski WP, Shawn Davison K, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris SP, Hodsman AB, Kendler D, McClung MR, Miller PD, Yuen CK. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther. 2004 Jan;26(1):15-28
Yanase T, Suzuki S, Goto K, Nomura M, Okabe T, Takayanagi R, Nawata H. Aromatase in bone: roles of Vitamin D3 and androgens. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):393-7.
Crescioli C, Maggie M, Vannelli GB, Luconi M, Salerno R, Barni T, Gulisano M, Forti G, Serio M. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab. 2000 Jul;85(7):2576-83.
Нет в наличии
- 20% → 1400
- 15% → 1488
- 10% → 1575
This product will be in stock on Monday 17 August, 2020.